Published 22 hours ago • loading... • Updated 21 hours ago

Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congress

Abbisko Therapeutics announced updated Phase 2 results of irpagratinib combined with atezolizumab for advanced hepatocellular carcinoma at the 2025 ESMO GI Congress in Barcelona.
The study emerged because about 30% of HCC patients show FGF19 overexpression and no FGFR4 inhibitor has global regulatory approval to date.
The combination demonstrated encouraging anti-tumor effects and a favorable safety profile in FGF19-positive advanced HCC patients, including those who were new to treatment as well as individuals with prior exposure to immune checkpoint inhibitors.
At the 2024 ESMO GI Congress, Abbisko reported a 50% objective response rate using 220mg irpagratinib BID with atezolizumab in FGF19+ HCC patients.
These results suggest irpagratinib-based combinations could become a breakthrough FGFR4-targeted therapy for advanced HCC with FGF19 overexpression.

Insights by Ground AI

Does this summary seem wrong?

34 Articles

All

Left

Center

Right

Montana Standard

+32 Reposted by 32 other sources

Center

Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congress

SHANGHAI, May 12, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (02256.HK) today announced that updated results from the phase 2 study of irpagratinib (ABSK011) in combination with atezolizumab for the treatment of advanced hepatocellular carcinoma (HCC) will be presented at…

22 hours ago

Read Full Article

Finnoexpert

Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congr - Finnoexpert

Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congr Source link The post Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congr appeared first on Finnoexp…

21 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year